TaiRx, Inc. (TPEX:6580)
Taiwan · Delayed Price · Currency is TWD 12.50
-0.45 (-3.47%)
Jul 14, 2026, 1:31 PM CST
TaiRx Revenue
In the year 2025, TaiRx had annual revenue of 27.88M TWD with 239.03% growth. TaiRx had revenue of 20.37M in the half year ending December 31, 2025, with 302.99% growth.
Revenue
27.88M
Revenue Growth
+239.03%
P/S Ratio
50.68
Revenue / Employee
n/a
Employees
n/a
Market Cap
1.41B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 27.88M | 19.65M | 239.03% |
| Dec 31, 2024 | 8.22M | 3.14M | 61.79% |
| Dec 31, 2023 | 5.08M | -1.84M | -26.59% |
| Dec 31, 2022 | 6.92M | 1.78M | 34.66% |
| Dec 31, 2021 | 5.14M | 1.78M | 53.05% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Synbio Tech | 1.02B |
| GenMont Biotech Incorporation | 390.95M |
| Abnova (Taiwan) | 348.71M |
| NeoCore Technology | 235.54M |
| Enimmune | 48.19M |
| Anti-Microbial Savior BioteQ | 706.00K |